Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
| Market Cap | 1.22B+1.9% |
| Revenue (ttm) | 252.00M+222.3% |
| Net Income | -220.76M+34.1% |
| EPS | -2.52+35.4% |
| Shares Out | 89.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,539,601 |
| Open | 14.08 |
| Previous Close | 14.15 |
| Day's Range | 13.62 - 14.35 |
| 52-Week Range | 12.79 - 25.59 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 36.67(+168.64%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SNDX
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating SNDX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 2, 2026Earnings report
Ask Barron about SNDX
$SNDX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SNDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SNDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SNDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SNDX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Biopharmaceutical Cancer Therapeutics Member | $72.79M | 79.94% |
| Stock-based compensation | $14.01M | 15.39% |
| Cost of Product Sales | $3.21M | 3.52% |
| Other R&D programs | $1.04M | 1.15% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SNDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SNDX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SNDX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $53.59M |
| XBIState Street SPDR S&P Biotech ETF | $37.67M |
| IWMiShares Russell 2000 ETF | $31.61M |
| VXFVanguard Extended Market ETF | $19.06M |
| IWOiShares Russell 2000 Growth ETF | $11.95M |
| VTWOVanguard Russell 2000 ETF | $9.73M |
Estimated from each fund’s disclosed top holdings × AUM
SNDX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SNDX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 100 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 60.1
What’s Behind the Score
News check: Prestigious product award and positive regulatory validation outweigh expected negative Q3 earnings for this clinical-stage biotech.